A randomized multicenter non-inferiority phase III trial of chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab,N0,M0 rectal cancer (the TAUTEM study)
According to international guidelines, the standard treatment of stage T2-T3ab,N0,M0 rectal cancer is total mesorectal excision (TME). The TAUTEM study is a multicenter phase III trial designed to assess an alternative treatment that preserves the rectum applying oncological non-inferiority criter...
| Autor: | |
|---|---|
| Tipo de recurso: | conjunto de datos |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Consorci de Serveis Universitaris de Catalunya (CSUC) |
| Repositorio: | CORA.Repositori de Dades de Recerca |
| OAI Identifier: | oai:dnet:cora.rdr____::e18ae0f80d37e535d7efd0734116cbd8 |
| Acceso en línea: | https://doi.org/10.34810/DATA1181 |
| Access Level: | acceso abierto |
| Palabra clave: | Medicine, Health and Life Sciences Rectal cancer Rectal neoplasms Neoadjuvant treatment and rectal cancer Local excision and rectal cancer Transanal endoscopic microsurgery (TEM) Mesorectal excision (TME) |
| Sumario: | According to international guidelines, the standard treatment of stage T2-T3ab,N0,M0 rectal cancer is total mesorectal excision (TME). The TAUTEM study is a multicenter phase III trial designed to assess an alternative treatment that preserves the rectum applying oncological non-inferiority criteria |
|---|